Literature DB >> 4099624

Possible effect of measles on leukaemia.

G Pasquinucci.   

Abstract

Entities:  

Mesh：

Year:  1971        PMID： 4099624     DOI： 10.1016/s0140-6736(71)90869-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  26 in total

1.  Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?

Authors:  Jay D Naik; Christopher J Twelves; Peter J Selby; Richard G Vile; John D Chester
Journal:  Clin Cancer Res       Date:  2011-05-16       Impact factor: 12.531

2.  Some 'in vitro' effects of bacterial filtrates on normal lymphocytes and leukaemic cells.

Authors:  J de Azavedo; J F Greally
Journal:  Ir J Med Sci       Date:  1975-12       Impact factor: 1.568

Review 3.  Intratumoral Immunotherapy-Update 2019.

Authors:  Omid Hamid; Rubina Ismail; Igor Puzanov
Journal:  Oncologist       Date:  2019-11-29

Review 4.  Attenuated oncolytic measles virus strains as cancer therapeutics.

Authors:  P Msaouel; I D Iankov; A Dispenzieri; E Galanis
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

Review 5.  Potential and clinical translation of oncolytic measles viruses.

Authors:  Steven Robinson; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2017-03       Impact factor: 4.388

6.  Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics.

Authors:  G Ungerechts; M E Frenzke; K-C Yaiw; T Miest; P B Johnston; R Cattaneo
Journal:  Gene Ther       Date:  2010-08-05       Impact factor: 5.250

Review 7.  Oncolytic measles virus strains as novel anticancer agents.

Authors:  Pavlos Msaouel; Mateusz Opyrchal; Evidio Domingo Musibay; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2013-01-06       Impact factor: 4.388

8.  Picornavirus infection leading to immunosuppression.

Authors:  Matthew F Cusick; Jane E Libbey; Robert S Fujinami
Journal:  Future Virol       Date:  2014-05-01       Impact factor: 1.831

Review 9.  Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.

Authors:  Pavlos Msaouel; Angela Dispenzieri; Evanthia Galanis
Journal:  Curr Opin Mol Ther       Date:  2009-02

10.  Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.

Authors:  Evanthia Galanis; Lynn C Hartmann; William A Cliby; Harry J Long; Prema P Peethambaram; Brigitte A Barrette; Judith S Kaur; Paul J Haluska; Ileana Aderca; Paula J Zollman; Jeff A Sloan; Gary Keeney; Pamela J Atherton; Karl C Podratz; Sean C Dowdy; C Robert Stanhope; Timothy O Wilson; Mark J Federspiel; Kah-Whye Peng; Stephen J Russell
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.